Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).

@article{Kim2015ComparisonOI,
  title={Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).},
  author={Ji Soo Kim and Sung Hwan Kim and ByoungOh Kwon and SeungSuh Hong},
  journal={Expert review of clinical immunology},
  year={2015},
  volume={11 Suppl 1},
  pages={S33-41}
}
Anti-drug antibodies against biologic drugs affect efficacy and safety; therefore, it is important to use appropriate assays for immunogenicity testing in clinical studies. This review describes the electrochemiluminescent (ECL) immunoassay, ELISA, radioimmunoassay, and homogeneous mobility shift assay. The characteristics of ECL, used to assess immunogenicity in comparison trials of CT-P13 (Remsima(®), Inflectra(®)) versus its reference medicinal product, infliximab (Remicade(®)), are also… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS